Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca® (rucapar
Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report?
03:31pm, Thursday, 04'th Jun 2020
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
Clovis Oncology Reports New Recommendations For Rubraca Tablets In Updated National Comprehensive Cancer Network Guideliness
12:10pm, Thursday, 28'th May 2020
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new re
Edited Transcript of CLVS earnings conference call or presentation 5-May-20 8:30pm GMT
09:06am, Thursday, 28'th May 2020
Q1 2020 Clovis Oncology Inc Earnings Call
Clovis Oncology Option Alert: Jul 17 $10 Calls at the Ask: 526 @ $0.401 vs 4747 OI; Ref=$6.46
02:57pm, Wednesday, 27'th May 2020The Week Ahead In Biotech: ASCO Presentations In The Spotlight
12:00am, Sunday, 24'th May 2020
Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
HC Wainwright & Co. Reiterates Buy on Clovis Oncology, Lowers Price Target to $29
10:55am, Friday, 22'nd May 2020Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
08:10pm, Thursday, 21'st May 2020
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Clovis Oncology Needs a Savior
06:24pm, Thursday, 21'st May 2020
Cancer company has lost more than 90% of its market value in past five years Continue reading...
AstraZeneca/Merck's Lynparza Get FDA Nod for Prostate Cancer
12:00am, Thursday, 21'st May 2020
Stocks Analysis by Zacks Investment Research covering: Pfizer Inc, Clovis Oncology Inc, AstraZeneca PLC ADR. Read Zacks Investment Research's latest article on Investing.com
